ScienceOpen:
research and publishing network
For Publishers
Discovery
Metadata
Peer review
Hosting
Publishing
For Researchers
Join
Publish
Review
Collect
My ScienceOpen
Sign in
Register
Dashboard
Blog
About
Search
Advanced search
My ScienceOpen
Sign in
Register
Dashboard
Search
Search
Advanced search
For Publishers
Discovery
Metadata
Peer review
Hosting
Publishing
For Researchers
Join
Publish
Review
Collect
Blog
About
1
views
0
references
Top references
cited by
0
Cite as...
0 reviews
Review
0
comments
Comment
0
recommends
+1
Recommend
0
collections
Add to
0
shares
Share
Twitter
Sina Weibo
Facebook
Email
2,705
similar
All similar
Record
: found
Abstract
: not found
Article
: not found
Treatment of severe angiopathy with imipenem/cilastatin versus piperacillin/clindamycin
Author(s):
K.P. Bouter
,
F.J.L. Visseren
,
J.D. Banga
,
R. Verkooyen
,
K. Bartelink
,
R.J.A. Diepersloot
Publication date
Created:
September 1994
Publication date
(Print):
September 1994
Journal:
Atherosclerosis
Publisher:
Elsevier BV
Read this article at
ScienceOpen
Publisher
Review
Review article
Invite someone to review
Bookmark
Cite as...
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Related collections
Procedural speed in criminal law
Author and article information
Journal
Title:
Atherosclerosis
Abbreviated Title:
Atherosclerosis
Publisher:
Elsevier BV
ISSN (Print):
00219150
Publication date Created:
September 1994
Publication date (Print):
September 1994
Volume
: 109
Issue
: 1-2
Page
: 242
Article
DOI:
10.1016/0021-9150(94)93968-3
SO-VID:
69b9c88d-6c0f-4980-8308-d4088e122ed8
Copyright ©
© 1994
License:
https://www.elsevier.com/tdm/userlicense/1.0/
History
Data availability:
Comments
Comment on this article
Sign in to comment
scite_
Similar content
2,705
Meropenem versus imipenem/cilastatin in intra-abdominal infections requiring surgery. Meropenem Study Group.
Authors:
S Geroulanos
Imipenem/cilastatin encapsulated polymeric nanoparticles for destroying carbapenem-resistant bacterial isolates
Authors:
Mona Shaaban
,
Mohamed Shaker
,
Fatma M Mady
1159. Pharmacokinetics, Safety, and Tolerability of Imipenem/Cilastatin/Relebactam in Pediatric Participants With Confirmed or Suspected Gram-negative Bacterial Infections: A Phase 1b, Open-label, Single-Dose Clinical Trial
Authors:
John Bradley
,
Nataliia Makieieva
,
Camilla Tøndel
…
See all similar